Webinar Date/Time: Thursday, December 8, 2022 at 11am EST | 10am CST | 8 am PST
This webinar will highlight the challenges in in the field of mRNA-based therapeutics, a strategy to design mRNA-LNP process for at-scale manufacturing, and the importance of end-to-end service.
CDMO competition can be expected to intensify since mRNA manufacturing capacity and CDMOs’ capabilities both expanded significantly to meet the need associated with the pandemic. From a technical standpoint, the processes associated with mRNA manufacture generally are still new; this is pioneering work. This webinar will highlight the challenges in in the field of mRNA-based therapeutics, a strategy to design mRNA-LNP process for at-scale manufacturing, and the importance of end-to-end service. Lastly, the in-house capability of Samsung Biologics as mRNA CDMO company will be introduced.
Key Learning Objectives:
Executive Vice President, Head of Manufacturing
Pierre Catignol is the Executive Vice President and Head of Manufacturing at Samsung Biologics. He is a recognized industry expert with a demonstrated history of 26+ years in the biopharmaceutical and pharmaceutical industry. Prior to joining Samsung Biologics, Pierre held a leadership role at Lonza serving as the Head of the Portsmouth, NH (USA) and Porriño, Spain sites. He also served as Site Head at Virbac & Sanofi Pasteur, as well as Senior Vice President of Technical Operations & Supply Chain at Stallergenes Greer earlier in his career. Pierre holds a master's degree in general engineering from ECAM LaSalle.
Eunseo (Ency) Lee
Eunseo (Ency) Lee, Ph.D is the Senior Scientist of mRNA T/F at Samsung Biologics. After joining Samsung Biologics in 2021, she has led the tech transfer project in both lab- and at-scale lipid nanoparticle manufacturing process. She holds a Master/Ph.D degree in Chemical and Biological Engineering from Seoul National University, South Korea, and a bachelor’s degree in Chemical Engineering from University of Notre Dame, USA.